Fairvalue-Calculator Fairvalue-Calculator
EN DE

Gelteq Limited (GELS) Fair Value & Analysis

Healthcare · US · Market cap $11.1M

Price$0.6901
Fair Value$0.6800
Upside-1.5%
Quality87/100
Evidence: Low Range $0.5100 – $1.02

Fair value as of: Jun 25, 2026

Analysis

Gelteq Limited (GELS) currently trades at $0.6901, while our model-based Fair Value estimate is $0.6800 — implying the stock looks roughly 1.5% overvalued today. We read business quality at 87/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Gelteq Limited focuses on developing and commercializing white label gel-based delivery solutions for humans and animals in the United States of America, China and Australia. It offers edible gels for prescription drugs, nutraceuticals, pet care, and other products, as well as for sports and over-the-counter products. Gelteq Limited was incorporated in 2017 and is headquartered in Clayton, Australia.

Open the full interactive analysis →

Similar stocks

Takeda Pharmaceutical Company (TAKP34) +3193% Jiangsu Hengrui Pharmaceuticals Co (600276) -37% Sun Pharmaceutical Industries Limited (SUNPHARMA) -44% Zoetis Inc (Z1TS34) -1% Hansoh Pharmaceutical Group (3692) -37% Divi's Laboratories Limited (DIVISLAB) -70%

Frequently asked questions

Is Gelteq Limited (GELS) undervalued?
As of Jun 25, 2026, our model estimates a fair value of $0.6800 versus a price of $0.6901 — about −1% (overvalued). Model-based estimate, not financial advice.
What is the fair value of GELS?
Our 21-model fair value for Gelteq Limited is $0.6800 (as of Jun 25, 2026), built from audited fundamentals. The current price is $0.6901.
What is the quality score of GELS?
Gelteq Limited has a Quality Score of 87/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.